scholarly journals Fibrotic lung toxicity induced by cytotoxic drugs, radiation and immunotherapy in patients treated for lung cancer

2018 ◽  
Vol 88 (2) ◽  
Author(s):  
Elena Bargagli ◽  
Viola Bonti ◽  
Alessandra Bindi ◽  
Vieri Scotti ◽  
Massimo Pistolesi ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Lung Toxicity ◽  
Lung Damage ◽  
Radiation Recall ◽  
Cryptogenic Organizing Pneumonia ◽  
Immune Mediated ◽  
Radiological Pattern ◽  
High Doses ◽  
Recall Pneumonitis ◽  
Immune Suppressor

Patients treated for lung cancer may develop lung toxicity induced by chemotherapy (DILD), radiation or combined radiation recall pneumonitis. In the literature, some cases of immune-mediated pneumonitis have been reported associated with immunotherapy. The clinical and radiologic features of interstitial lung toxicity are unspecific, dyspnoea and dry cough are the most common symptoms while the most frequent radiological pattern is the cryptogenic organizing pneumonia (COP). Why only some individuals treated with these drugs develop interstitial lung toxicity is unclear.In the last few years some studies have reported the utility of KL 6 for the evaluation of DILD. The treatment is based on high doses of systemic steroids or immune suppressor. In this study we report severe interstitial lung damage in patients treated with different anti-blastic, immune and radiation therapies. Treated with surgery, chemotherapy, immuno and radiotherapy for lung cancer, they unfortunately died of severe DILD.

scholarly journals Dramatic Radiation Recall Pneumonitis Induced by Osimertinib after Palliative Thoracic Radiotherapy for Lung Cancer

2019 ◽  
Vol 14 (10) ◽  
pp. e224-e226 ◽  
Author(s):  
Mateo Sanchis-Borja ◽  
Antoine Parrot ◽  
Déborah Sroussi ◽  
Eleonor Rivin del Campo ◽  
Vincent Fallet ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Thoracic Radiotherapy ◽  
Radiation Recall ◽  
Recall Pneumonitis

scholarly journals Radiation recall pneumonitis induced by chemotherapy after thoracic radiotherapy for lung cancer

2011 ◽  
Vol 6 (1) ◽  
pp. 24 ◽  
Author(s):  
Xiao Ding ◽  
Wei Ji ◽  
Junling Li ◽  
Xiangru Zhang ◽  
Luhua Wang
Keyword(s):  
Lung Cancer ◽  
Thoracic Radiotherapy ◽  
Radiation Recall ◽  
Recall Pneumonitis

Clinical characteristics of nivolumab-induced radiation recall pneumonitis in patients with non-small cell lung cancer: A multicenter real-world analysis of 669 patients.

2020 ◽  
Vol 38 (5_suppl) ◽  
pp. 88-88 ◽  
Author(s):  
Tadasuke Shimokawaji ◽  
Shoko Narita ◽  
Tomoyuki Naito ◽  
Hibiki Udagawa ◽  
Koichi Goto ◽  
...  
Keyword(s):  
Risk Factors ◽  
Lung Cancer ◽  
Clinical Characteristics ◽  
Significant Risk ◽  
Small Cell ◽  
Small Cell Lung ◽  
Radiation Recall ◽  
Lung Cancer Patients ◽  
History Of ◽  
Recall Pneumonitis

88 Background: Immune checkpoint inhibitors can cause immune-related pneumonitis in lung cancer patients. Some of those patients with history of previous thoracic radiation therapy (TRT) are reported to show radiation recall pneumonitis (RRP) pattern. In this multicenter retrospective study, we analyzed the patient background and clinical characteristics of RRP. Methods: Medical records of non-small cell lung cancer patients, who received nivolumab between December 2015 and March 2017, were retrospectively reviewed. Incidence of pneumonitis, and incidence, risk factors and clinical characteristics of RRP were analyzed at 5 institutions. Person’s chi-square test (age, sex, smoking history, performance status at the start of nivolumab treatment, background lung disease, history of previous radiation pneumonitis, total dose, volume receiving more than 20Gy, 30Gy, mean lung dose of TRT, and duration after TRT) was conducted to identify potential risk factors of RRP. RRP was defined as fibrosis or consolidation occurring in the previous TRT field, and imaging analysis was conducted by two individual radiologists. Results: A total of 669 patients were evaluated, and the incidences of all-grade and ≥ grade 3 pneumonitis were 8.8% (59/669) and 6.2% (18/669), respectively. Incidence of RRP was 5.4% (14/257) among patients with history of previous TRT. There were no significant risk factors for RRP. Although we did not find significant difference between the severity of RRP pattern and other radiological patterns of pneumonitis, patients with RRP showed better outcome. All patients recovered from RRP without no exacerbation or death, compared to 9.3% of exacerbation or death in other patterns of pneumonitis. Conclusions: Incidence of RRP was 5.4% among patients with history of previous TRT, although there were no significant risk factors of RRP. Patients with RRP pattern showed relatively better outcome.

Immunomodulating functions of recombinant ovine interferon tau: potential for therapy in mulitple sclerosis and autoimmune disorders

1998 ◽  
Vol 4 (2) ◽  
pp. 63-69 ◽  
Author(s):  
O A Khan ◽  
H Jiang ◽  
P S Subramaniam ◽  
H M Johnson ◽  
S S Dhib-Jalbut
Keyword(s):  
Therapeutic Option ◽  
High Dose ◽  
Interferon Tau ◽  
Unique Type ◽  
Immune Mediated ◽  
High Concentrations ◽  
Ifn Treatment ◽  
High Doses ◽  
Mulitple Sclerosis

The interferons (IFN) are a family of complex proteins possessing antiviral, antiproliferative, and immunomodulatory activities. Two type 1 recombinant human IFN have been recently approved for the treatment of multiple sclerosis (MS). However, use of high dose type 1 IFN treatment in MS patients has been limited by dose-related toxicity. Ovine IFNt is a unique type 1 interferon discovered for its role in the animal reproductive cycle. It differs from other type 1 IFNs in that it is remarkably less toxic even at high concentrations, is able to cross species barriers, and is not inducible by viral infection. Ovine IFNt has been shown to be very effective in the treatment of animal models of MS. In this study, we examined the toxicity of OvIFNt on human T-cells at high doses and its immunregulatory properties at equivalent doses. Our experiments confirmed the remarkably non-toxic nature of OvIFNt on human cells at high concentrations as well as immunomodulating properties consistent with other type 1 IFNs including an antilymphoproliferative effect and inhibition of IFNg-induced HLA class II expression. These results suggest that OvIFNt could be developed into a potentially less toxic therapeutic option for immune-mediated disorders including MS.

Sign in / Sign up

Export Citation Format

Share Document